Kardium Secures $250 Million to Launch Innovative Globe System for Atrial Fibrillation Treatment

Which Company is Investing in Improving a Specific Treatment?

Kardium Inc., a founder of the ‘Globe® Pulsed field system’, which is an innovative treatment for atrial fibrillation (AF), has increased its investment to US$250 million. The financing round consists of new investors such as Eckuity Capital, Qatar Investment Authority (QIA), Eventide Asset Management, Janus Henderson investors, MMCAP, and Piper Heartland Healthcare Capital. The presence of existing investors, including accounts and funds suggested by Durable Capital Partners LP, T Rowe Price Investment Management Inc., and T. Rowe Price Associates Inc., witnessed the investment. The financing involves a known strategic investor.

Innovation and Funds

The current Heart Rhythm Society annual meeting 2025 witnessed excellent clinical data, referring to a crucial PULSAR clinical study of the Globe system. The data showed satisfying results along with the Globe system. The data represents an atrial arrhythmia-free in 1 year of 78% in patients suffering from paroxysmal AF and 0% safety events (device-related). Kardium’s upcoming innovation is poised for official launch, and the new funding will enhance its innovative efforts to serve the healthcare market effectively.

Regarding which the new funding will help Kardium to receive regulatory approval for the Globe system. This financing will extend production capacity and manufacturing facilities. Also, it will contribute the highest to building a commercial team and clinical trial. These all plans are a preparation for the official launch of the Globe system that will be commercialized this year. The launch is a ticket to clinical research for other applications and expansion to certain areas for the global system.

The Globe system has a single catheter with advanced software and a 122-electrode array, is a significant part of further clinical study.

Views and Statements

CEO of Kardium, Kevin Chaplin, said, “We’re proud to be able to finance along with the commendable investors. This funding helps us move forward to launch the Globe system. Kardium’s staff is excited to see the Globe system in the market and its contribution to the lives of millions of patients globally, those suffering from atrial fibrillation.”

Portfolio Manager at Janus Henderson Investors, Aaron Schaechterle, said, “We are excited to be a part of Kardium as an investor. The Globe system is an attractive innovation with a remarkable clinical outcome. It is a unique development and milestone in the AF treatment. We are honored to introduce Kardium’s ultra-modern technology to the global market.”